April 26, 2012
1st quarter of 2012:

Encouraging start to the year for Bayer

Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience - increases at HealthCare - continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed
Leverkusen, April 26, 2012 - The Bayer Group saw a successful start to 2012. "All the subgroups contributed to the encouraging increase in sales, particularly CropScience, which experienced a strong start to the season," Management Board Chairman Dr. Marijn Dekkers explained on Thursday when the first-quarter interim report was published. Earnings of the Group rose sharply. "In view of the good start to 2012, we are increasingly confident for the rest of the year," Dekkers added. Given the continuing uncertainties, however, he said Bayer is currently adhering to the guidance for 2012 that was issued at the end of February.

Sales of the Bayer Group advanced by 6.8 percent in the first quarter, to a record EUR 10,056 million (Q1 2011: EUR 9,415 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), business expanded by 5.2 percent. The operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million (Q1 2011: EUR 1,148 million). Special items totaled minus EUR 169 million (Q1 2011: minus EUR 442 million). EBIT before special items rose by 13.6 percent to EUR 1,806 million (Q1 2011: EUR 1,590 million). Earnings before interest, taxes, depreciation and amortization (EBITDA) - before special items - improved by 9.4 percent to EUR 2,442 million (Q1 2011: EUR 2,232 million). This was partly due to positive currency effects of EUR 85 million, which occurred mainly at Health Care and CropScience. Net income increased by 53.5 percent to EUR 1,050 million (Q1 2011: EUR 684 million). Core earnings per share rose by 15.9 percent to EUR 1.68 (Q1 2011: EUR 1.45).

Gross cash flow moved ahead by 21.8 percent to EUR 1,595 million (Q1 2011: EUR 1,309 million) due to the improved operating performance. Net cash flow, however, was down by 66.2 percent year on year at EUR 271 million (Q1 2011: EUR 801 million), because cash tied up in working capital increased markedly due to the expansion of business. Net financial debt fell since the start of the year from EUR 7.0 billion to EUR 6.9 billion as of March 31, mainly as a result of positive currency effects.

HealthCare posts gains especially in emerging markets

Sales of the HealthCare subgroup increased by 4.2 percent in the first quarter, to EUR 4,342 million (Q1 2011: EUR 4,166 million). After adjusting for currency and portfolio effects, sales were up by 2.1 percent. "The Pharmaceuticals and Consumer Health segments both contributed to this growth. Business developed particularly well in the emerging markets as a whole," explained Dekkers.

Sales in the Pharmaceuticals segment rose by 1.6 percent (Fx & portfolio adj.) to EUR 2,517 million. Growth was achieved mainly in the emerging markets, especially China, while sales were slightly down in most European countries. Among the segment's best-selling products, AspirinTM Cardio for the prevention of myocardial infarction posted a significant sales gain of 15.7 percent on a currency-adjusted (Fx adj.) basis. Revenues from the hormone-releasing intrauterine device MirenaTM (Fx adj. plus 8.3 percent), the cancer drug NexavarTM (Fx adj. plus 4.5 percent) and the blood-clotting product KogenateTM (Fx adj. plus 1.9 percent) also developed positively. Following market launches in further countries and the expansion of indications, the anticoagulant XareltoTM entered the list of Bayer's best-selling pharmaceutical products for the first time. By contrast, sales of the antibiotic AvaloxTM/AveloxTM (Fx adj.
minus 13.3 percent) and the erectile dysfunction treatment LevitraTM (Fx adj.
minus 9.3 percent) were down because of a partial restructuring of distribution
for general medicine products in the United States.

Sales in the Consumer Health segment rose by 2.9 percent (Fx & portfolio adj.)
to EUR 1,825 million, with all divisions contributing to growth. Business
developed especially well in the emerging markets. In the Consumer Care
Division (non-prescription medicines), the skincare product BepanthenTM/
BepantholTM (Fx adj. plus 7.7 percent) performed particularly well, while sales
of the analgesic AleveTM/naproxen and the One A DayTM line of dietary supplements
matched the good prior-year level. Sales of the analgesic AspirinTM declined by
7.0 percent (Fx adj.) from the high level of the prior-year quarter. The
Medical Care Division benefited mainly from the positive development of the
contrast agent and medical equipment business. Sales of the contrast agent
GadovistTM climbed by 26.5 percent (Fx adj.). Among the diabetes care products,
sales of the ContourTM line of blood glucose meters rose by 7.3 percent (Fx
adj.). In the Animal Health Division, sales of the AdvantageTM line of flea,
tick and worm control products advanced by 16.2 percent (Fx adj.).

EBITDA before special items of Bayer HealthCare increased by 3.6 percent to EUR
1,181 million (Q1 2011: EUR 1,140 million). This was largely attributable to
the positive business development and effective cost management in both

Growth in all CropScience businesses

Sales at CropScience advanced by 15.6 percent (Fx & portfolio adj. 14.4
percent) to EUR 2,610 million (Q1 2011: EUR 2,257 million). With good market
conditions continuing, the subgroup grew all areas of its business. "The season
got off to an early and promising start in the northern hemisphere," Dekkers
explained. Bayer CropScience achieved its highest growth rates in North America
at 24.8 percent (Fx adj.), followed by Asia/Pacific at 22.7 percent (Fx adj.).
Sales increased by 5.2 percent (Fx adj.) in Europe and by 8.9 percent (Fx adj.)
in Latin America/Africa/Middle East.

Crop Protection posted growth in all product groups. Sales of herbicides and
fungicides advanced by 19.0 and 12.3 percent, respectively (Fx & portfolio
adj.). Sales of insecti-cides increased by 17.4 percent (Fx & portfolio adj.),
mainly benefiting from a rejuvenated portfolio. Business with seed treatment
products expanded by 3.2 percent (Fx adj.).

The BioScience business, which specializes in seed and plant traits, improved
sales by 17.1 percent (Fx & portfolio adj.). Here, the largest increases were
achieved for canola and cotton seed in North America, while the vegetable seed
business showed a moderate decline in sales against a strong prior-year
quarter. Sales of the Environmental Science business group advanced by 3.4
percent (Fx adj.).

EBITDA before special items of Bayer CropScience climbed by 31.7 percent to EUR
981 million (Q1 2011: EUR 745 million). Earnings growth - mainly the result of
an early start to the season and considerably higher volumes - was also helped
by efficiency improvements, successful cost management and positive currency
effects. In addition, the subgroup benefited from one-time gains of EUR 22
million (Q1 2011: EUR 0 million) in connection with divestments and from the
earlier receipt of royalty payments.

MaterialScience burdened by persisting high raw material costs

Sales of the high-tech materials business rose by 3.8 percent (Fx & portfolio
adj. 2.5 percent) in the first quarter, to EUR 2,788 million (Q1 2011: EUR
2,686 million). "Bayer MaterialScience achieved higher volumes in all regions,
while selling prices as a whole were level with the prior-year quarter," said
Dekkers. Price increases in the Latin America/Africa/Middle East, North America
and Europe regions offset declines in Asia/Pacific. "However, earnings of
MaterialScience remained under pressure because of high raw material costs," he

Business with raw materials for foams (Polyurethanes) improved by 4.7 percent
(Fx & portfolio adj.), while high-tech plastics (Polycarbonates) were down by
4.2 percent (Fx & portfolio adj.) mainly as a result of lower selling prices.
Sales of raw materials for coatings, adhesives and specialties improved by 3.9
percent (Fx & portfolio adj.) thanks to growth in all product groups, while the
Industrial Operations unit grew by 8.9 percent (Fx & portfolio adj.).

EBITDA before special items of Bayer MaterialScience was down by 19.4 percent
year on year at EUR 278 million (Q1 2011: EUR 345 million). However, earnings
more than doubled against the weak fourth quarter of 2011 (EUR 106 million).
Earnings were diminished above all by a rise in raw material costs, while
higher operating costs also had a negative impact. Positive effects came from
efficiency improvement programs, increased volumes and one-time gains of EUR 19
million (Q1 2011: EUR 0 million) on the acquisition of the remaining interest
in the joint venture Baulé S.A.S.

Increasing confidence for the rest of 2012

In view of the good start to 2012, Bayer is increasingly confident for the rest
of the year. Given the continuing uncertainties, however, the company is
currently adhering to the guidance for the full year 2012 that it issued at the
end of February. For the full year 2012, Bayer continues to forecast a
currency- and portfolio-adjusted sales increase of about 3 percent. This would
result in Group sales of approximately EUR 37 billion based on unchanged
exchange rate assumptions (e.g. EUR 1 = US$1.40). Bayer continues to plan a
slight improvement in EBITDA before special items. This will be driven by
HealthCare and CropScience, while earnings at MaterialScience are likely to be
flat with 2011 in view of the currently difficult market conditions. Bayer also
plans to slightly improve core earnings per share.

The outlook for 2012 at Bayer HealthCare is confirmed. This subgroup's top
priority for 2012 is to successfully commercialize the new pharmaceutical
products. HealthCare expects sales to increase by a low- to mid-single-digit
percentage (Fx & portfolio adj.). The subgroup plans to slightly improve EBITDA
before special items, although earnings are likely to be hampered by higher
marketing expenses and the effects of the genericization of YasminTM in Europe.
Sales of the Pharmaceuticals segment in 2012 are forecasted to remain stable or
move slightly higher on a currency- and portfolio-adjusted basis, and EBITDA
before special items to approximately match the prior-year level. In its
Consumer Health segment, the subgroup anticipates mid-single-digit growth in
currency- and portfolio-adjusted sales and in EBITDA before special items.

Bayer expects market conditions for its CropScience business to remain
favorable in 2012, and predicts above-market growth. Following the strong start
to the year, the guidance issued in February, according to which CropScience
anticipates that currency- and portfolio-adjusted sales and EBITDA before
special items will advance by mid-single-digit percentages, may be adjusted
upon publication of the next interim report, depending on future business

The market environment for Bayer MaterialScience developed as expected in the
first quarter. This subgroup continues to plan for currency- and
portfolio-adjusted sales and EBITDA before special items in 2012 to remain
level with the prior year. Should the market environment develop more favorably
than anticipated, MaterialScience expects sales and earnings to increase
accordingly. Currency- and portfolio-adjusted sales are expected to improve and
EBITDA before special items to come in significantly higher in the second
quarter of 2012 than in the first quarter.

The tables below contain the key data for the Bayer Group and its subgroups for
the first quarter 2012.

The complete financial report as of March 31, 2012 is available for online
viewing and download at www.investor.bayer.com.

Supplementary features at www.investor.bayer.com:
- presentation charts for the investor conference call at 12:00 noon CEST
- live webcast of the investor conference call from approximately 2:00 p.m. CEST
- recording of the investor conference call from approximately 6:00 p.m. CEST

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at www.bayer.com. The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or